Literature DB >> 30788231

Predictors of pneumonitis-free survival following lung stereotactic body radiation therapy.

Sibo Tian1, Jeffrey M Switchenko2, Richard J Cassidy1, Chase E Escott1, Richard Castillo1, Pretesh R Patel1, Walter J Curran1, Kristin A Higgins1.   

Abstract

BACKGROUND: Radiation pneumonitis is a common toxicity following lung stereotactic body radiation therapy (SBRT). We explored whether motion management technique, in conjunction with patient and treatment characteristics, is a predictor of radiation pneumonitis-free survival (PNFS).
METHODS: A single institution multi-center lung SBRT database was retrospectively reviewed. PNFS was defined as time to earliest onset of radiation pneumonitis or last clinical follow-up. Patients were simulated using a 4-dimensional approach, and those with 1 cm or greater tumor motion were selected for respiratory-gated treatment. Real-time Position Management and phase-based gating were employed. Univariate and multivariable Cox proportional hazard models were fit for relevant covariates to determine the impact of free-breathing versus respiratory-gated treatment on PNFS.
RESULTS: The initial treatment courses of 208 patients were included, with a median follow-up length of 23 months. The median age at treatment was 71 years. About 91.8% of patient had early stage (T1-2) non-small cell lung cancer and were treated with common regimens including 10 Gy ×5, 12 Gy ×4 and 18 Gy ×3; 26.4% underwent respiratory-gated SBRT. The overall rate of grade 3 or higher radiation pneumonitis was 10.1%. PNFS was not significantly different between patients treated with respiratory-gated versus free-breathing SBRT (HR =0.88; P=0.707); tumor location and fractionation were predictors of PNFS in the multivariate setting.
CONCLUSIONS: The method of motion management does not appear to impact PNFS when the tolerance for tumor displacement is 1 cm or less for free-breathing treatment planning and delivery. This approach may be appropriate when selecting patients for respiratory gating.

Entities:  

Keywords:  Non-small cell lung carcinoma; motion management; radiation pneumonitis; respiratory gating; stereotactic body radiation therapy (SBRT)

Year:  2019        PMID: 30788231      PMCID: PMC6351398          DOI: 10.21037/tlcr.2018.10.11

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  31 in total

1.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

Authors:  Robert Timmerman; Ronald McGarry; Constantin Yiannoutsos; Lech Papiez; Kathy Tudor; Jill DeLuca; Marvene Ewing; Ramzi Abdulrahman; Colleen DesRosiers; Mark Williams; James Fletcher
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

2.  A solution to the problem of monotone likelihood in Cox regression.

Authors:  G Heinze; M Schemper
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

3.  Benefit of respiration-gated stereotactic radiotherapy for stage I lung cancer: an analysis of 4DCT datasets.

Authors:  René W M Underberg; Frank J Lagerwaard; Ben J Slotman; Johan P Cuijpers; Suresh Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-01       Impact factor: 7.038

4.  The management of respiratory motion in radiation oncology report of AAPM Task Group 76.

Authors:  Paul J Keall; Gig S Mageras; James M Balter; Richard S Emery; Kenneth M Forster; Steve B Jiang; Jeffrey M Kapatoes; Daniel A Low; Martin J Murphy; Brad R Murray; Chester R Ramsey; Marcel B Van Herk; S Sastry Vedam; John W Wong; Ellen Yorke
Journal:  Med Phys       Date:  2006-10       Impact factor: 4.071

5.  Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of non-small-cell lung cancer.

Authors:  Ina Kyas; Holger Hof; Jürgen Debus; Wolfgang Schlegel; Christian P Karger
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-09       Impact factor: 7.038

Review 6.  Deep inspiration breath hold and respiratory gating strategies for reducing organ motion in radiation treatment.

Authors:  Gikas S Mageras; Ellen Yorke
Journal:  Semin Radiat Oncol       Date:  2004-01       Impact factor: 5.934

7.  Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.

Authors:  Umberto Ricardi; Andrea Riccardo Filippi; Alessia Guarneri; Francesca Romana Giglioli; Cristina Mantovani; Christian Fiandra; Silvia Anglesio; Riccardo Ragona
Journal:  Acta Oncol       Date:  2009       Impact factor: 4.089

8.  Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy.

Authors:  Matthias Guckenberger; Thomas Krieger; Anne Richter; Kurt Baier; Juergen Wilbert; Reinhart A Sweeney; Michael Flentje
Journal:  Radiother Oncol       Date:  2008-10-04       Impact factor: 6.280

9.  Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.

Authors:  Si Yeol Song; Wonsik Choi; Seong Soo Shin; Sang-Wook Lee; Seung Do Ahn; Jong Hoon Kim; Hyoung Uk Je; Charn Il Park; Jung Shin Lee; Eun Kyung Choi
Journal:  Lung Cancer       Date:  2009-01-24       Impact factor: 5.705

10.  Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.

Authors:  Hideomi Yamashita; Keiichi Nakagawa; Naoki Nakamura; Hiroki Koyanagi; Masao Tago; Hiroshi Igaki; Kenshiro Shiraishi; Nakashi Sasano; Kuni Ohtomo
Journal:  Radiat Oncol       Date:  2007-06-07       Impact factor: 3.481

View more
  2 in total

1.  The Protective Effects and Mechanism of Doxepin on Radiation-Induced Lung Injury in Rats.

Authors:  Xinlong Wan; Xuan Shi; Mengke Li; Qing Chen; Chang Xue; Guanghui Li; Yeke Huang; Jingwen Yang; Chan Chen; Zhiyi Wang; Shumei Ma; Xiaodong Liu
Journal:  Dose Response       Date:  2022-06-07       Impact factor: 2.623

2.  The protective effects of granulocyte-macrophage colony-stimulating factor against radiation-induced lung injury.

Authors:  Dan Hu; Yan Zhang; Ruiqi Cao; Yuying Hao; Xiaoye Yang; Tiantian Tian; Jiandong Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.